Abivax (AAVXF) Capital Expenditures (2024 - 2026)

Abivax has reported Capital Expenditures for 3 years, with the latest figure at -$63220.3 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 36.6% year-over-year to -$63220.3 in Q1 2026; TTM through Mar 2026 was -$165.3 million, a 75.83% increase from a year earlier, with the FY2025 full-year figure at -$165.3 million, up 75.83% from the prior year.
• Capital Expenditures was -$63220.3 for Q1 2026 at Abivax, up from -$165.2 million in the prior quarter.
• The five-year high for Capital Expenditures was $9352.4 in Q3 2025, with the low at -$683.3 million in Q4 2024.
• Average Capital Expenditures over 3 years is -$94.4 million, with a median of -$63220.3 recorded in 2026.
• The largest YoY upside for Capital Expenditures was 102.74% in 2025 against a maximum downside of 255.03% in 2025.
• Over 3 years, Capital Expenditures stood at -$683.3 million in 2024, then jumped by 75.82% to -$165.2 million in 2025, then surged by 99.96% to -$63220.3 in 2026.
• The last three Capital Expenditures figures came in at -$63220.3 (Q1 2026), -$165.2 million (Q4 2025), and $9352.4 (Q3 2025), per Business Quant data.